You are here

Non-Invasive Intraoral LED Phototherapy Device for the Prevention and Treatment of Oral Mucositis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DE026082-01
Agency Tracking Number: R43DE026082
Amount: $220,352.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDCR
Solicitation Number: PA15-269
Solicitation Year: 2016
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-04-01
Award End Date (Contract End Date): 2017-10-31
Small Business Information
8443 DOW CIR
Strongsville, OH 44136-1759
United States
DUNS: 108631797
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (440) 243-8401
Business Contact
Phone: (440) 243-8401
Research Institution

DESCRIPTION provided by applicant The goal of this SBIR is to create a novel phototherapeutic light delivery device which will advance the standard of care for the prevention and treatment of Oral Mucositis OM OM is one of the most common and highly significant toxicities of cancer therapy Approximately patients are affected by OM in the United States each year OM is an extremely painful condition which breaks down the lining of the mouth and is associated with increased treatment breaks increased day mortality and a considerable increase in healthcare costs The standard of care for patients with OM is mainly palliative aiming to reduce pain inflammation and risk of infection A new proven and powerful approach for both treatment and prevention of OM is Phototherapy PT Near Infrared light increases the production of ATP which protects the mucosa from cell death No reported side effects are observed from using phototherapy for the treatment of OM Current barriers to the use of phototherapy include the cost of laser equipment labor intensiveness inter operator variability and inconsistent light penetration Lumitex PT is developing a flexible biocompatible
silicone light guide to irradiate the entire oral mucosa with therapeutic light The key innovation
is the simultaneous irradiation of the entire oral cavity with minimal clinical supervision while significantly increasing patient comfort and compliance Our light delivery technology can be integrated into a mouthpiece that safely delivers J cm of NIR light directly to the oral mucosa in a tolerable period of time and can demonstrate compliance To address this hypothesis we created these aims Construction and optimization of a device utilizing light guide technology to deliver phototherapeutic light to the entire oral mucosa simultaneously Manufacturing a device that meets the output and safety requirements detailed in this proposal will complete this aim Demonstration of patient compliance and safety in a controlled clinical environment A pilot study will be comprised of head and neck cancer patients undergoing radiation while receiving phototherapeutic treatment under conditions mimicking expected end use The device will be evaluated based on fitness for intended use and patient safety Upon completion of Phase I we will successfully have developed a phototherapeutic mouthpiece capable of delivering the required light dosage in an effective controlled manner During Phase II we will develop a manufacturable sterilizable cost effective iteration for commercialization and prove its clinical efficacy Our long term goal is to create a home based device for all patients at risk for developing Oral Mucositis allowing the clinician to control dosage and the patient to self administer

PUBLIC HEALTH RELEVANCE In this Phase I SBIR Lumitex plans to develop an intraoral phototherapeutic device for the treatment and prevention of Oral Mucositis Oral Mucositis is one of the most severe and debilitating side effects of Chemo and Radio therapy affecting more than people annually and can lead to $ in additional hospital charges per patient Patients are often unable to eat sleep or speak which leads to depression and social isolation We expect our non invasive device can provide a safe effective and tolerable treatment to eliminate this serious side effect

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government